NanoRepro AGXTER:NN6 +12.79%51 Pretax Margin % is -32.79% as of Jun. 2025. GuruFocus rates XTER:NN6 with a GF Score™ of 51/100 and a GF Value™ of €1.00 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, NanoRepro AG ranks worse than 68.47% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. NanoRepro AG's Pre-Tax Income for the
six
months ended in Jun. 2025 was €-0.84 Mil. NanoRepro AG's Revenue for the
six
months ended in Jun. 2025 was €2.57 Mil. Therefore, NanoRepro AG's pretax margin for the quarter that ended in Jun. 2025 was -32.79%.
The historical rank and industry rank for NanoRepro AG's Pretax Margin % or its related term are showing as below:
XTER:NN6'
s Pretax Margin % Range Over the Past 10 Years
Min: -220.64 Med: -51.27 Max: 23.81
Current: -31.97
XTER:NN6's Pretax Margin % is ranked worse than 68.47% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.56
vs XTER:NN6: -31.97
NanoRepro AG (XTER:NN6) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
NanoRepro AG Pretax Margin % Related Terms
NanoRepro AG Pretax Margin % Historical Data
* Premium members only.
The historical data trend for NanoRepro AG's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:NN6 vs TMO, DHR, IDXX: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, NanoRepro AG's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NanoRepro AG Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, NanoRepro AG's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where NanoRepro AG's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NanoRepro AG (XTER:NN6) has a Pretax Margin % of -32.79% as of Jun. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on NanoRepro AG and its competitors. According to the industry distribution chart, NanoRepro AG ranks #139 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 68.5%.
Is NanoRepro AG's Pretax Margin % too high?
NanoRepro AG's current Pretax Margin % is -32.79%. Based on the distribution chart, NanoRepro AG ranks #139 out of 203 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, NanoRepro AG has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NanoRepro AG's Pretax Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, NanoRepro AG ranks #139 out of 203 companies for Pretax Margin %. This places NanoRepro AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on NanoRepro AG and its competitors. NanoRepro AG's current Pretax Margin % is -32.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NanoRepro AG stock overvalued right now?
Based on GuruFocus' analysis, NanoRepro AG (XTER:NN6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.00, compared to a current price of €2.16 — trading 116% above its estimated fair value. The current Pretax Margin % is -32.79%. NanoRepro AG's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For NanoRepro AG (XTER:NN6), the current Pretax Margin % is -32.79% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NanoRepro AG (XTER:NN6) Overvalued in 2026?
Based on GuruFocus' analysis, NanoRepro AG stock appears to be overvalued.
The current stock price of €2.16 is trading 116% above its estimated GF Value™ of €1.00.
GuruFocus considers NanoRepro AG to be Significantly Overvalued.
Key valuation signals for XTER:NN6:
Pretax Margin %: -32.79%
GF Value™: €1.00 vs. price of €2.16 (116% above fair value)
No single metric tells the full story. See the XTER:NN6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NanoRepro AG is engaged in the development, manufacturing, and distribution of CE-certified rapid diagnostic tests (self-tests) and food supplements for both, home and professional use.
51GF Score
Get the complete analysis for XTER:NN6
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:NN6 has been successfully added to your 
